Hepion Pharmaceuticals

HEPA · NASDAQ

$0.12+$0.0179 (+17.53%)TodayMarket closed ·
Prev close $0.1021

Latest news

  • Press releaseACCESS Newswire

    Hepion Pharmaceuticals Receives Positive FDA Response on GV104 in Gambling Disorder, a Condition With No Approved Medication

  • Press releaseACCESS Newswire

    Hepion Pharmaceuticals Completes Acquisition of Gravitas Life Sciences and Provides Corporate Update

  • Press releaseGlobe Newswire

    Hepion Pharmaceuticals In-Licenses ctRNA Biomarker Assay to Facilitate Early Diagnosis and Surveillance of Hepatocellular Carcinoma

  • Press releaseGlobe Newswire

    Hepion Pharmaceuticals Announces Dr. Kaouthar Lbiati as Interim Chief Executive Officer

  • News

    12 Health Care Stocks Moving In Monday's After-Market Session

  • News

    12 Health Care Stocks Moving In Wednesday's Intraday Session

  • News

    12 Health Care Stocks Moving In Wednesday's Intraday Session

  • News

    12 Health Care Stocks Moving In Tuesday's Intraday Session

  • News

    12 Health Care Stocks Moving In Thursday's Intraday Session

  • News

    12 Health Care Stocks Moving In Thursday's Pre-Market Session

  • NewsAvi Kapoor

    Why Intel Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket

  • News

    12 Health Care Stocks Moving In Wednesday's After-Market Session

  • News

    12 Health Care Stocks Moving In Wednesday's Intraday Session

  • NewsAvi Kapoor

    Crude Oil Edges Lower; Abbott Laboratories Posts Weak Sales

  • NewsAvi Kapoor

    Nasdaq Surges 1.5%; Procter & Gamble Posts Upbeat Earnings

  • NewsAvi Kapoor

    US Stocks Higher; Netflix Profit Beats Estimates

  • News

    12 Health Care Stocks Moving In Wednesday's Pre-Market Session

  • Press releaseGlobe Newswire

    Pharma Two B Announces Poster Presentation on P2B001 at the Annual Meeting of the Parkinson's Disease Study Group

  • News

    Pharma Two B And Hepion Pharmaceuticals Announce SEC Approval Of Registration Statement For Proposed Merger; Closing Expected Q4 2024 Pending Shareholder And Regulatory Approvals, Nasdaq Listing

  • Press releaseGlobe Newswire

    Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Effectiveness of Registration Statement Related to Proposed Merger

  • News

    12 Health Care Stocks Moving In Friday's Pre-Market Session

  • NewsAvi Kapoor

    Why Deckers Outdoor Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket

  • Press releaseGlobe Newswire

    Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Filing of Registration Statement on Form F-4 Related to Proposed Merger

  • News

    Market-Moving News for July 22nd

  • Press releaseGlobe Newswire

    Pharma Two B Announces Plans to Go Public via Merger with Hepion Pharmaceuticals, Inc. and Concurrent $11.5 Million Private Placement

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.